Cargando…

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?

INTRODUCTION: Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to support a diagnosis of Alzheimer's disease. Several preanalytical factors may alter the CSF concentrations of amyloid β 1–42 (Aβ1–42) in particular with the potential to influence diagnosis. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paterson, Ross W., Toombs, Jamie, Chapman, Miles D., Nicholas, Jennifer M., Heslegrave, Amanda J., Slattery, Catherine F., Foulkes, Alexander J.M., Clark, Camilla N., Lane, Christopher A.S., Weston, Philip S.J., Lunn, Michael P., Fox, Nick C., Zetterberg, Henrik, Schott, Jonathan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	CSF Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877931/ https://www.ncbi.nlm.nih.gov/pubmed/27239518 http://dx.doi.org/10.1016/j.dadm.2015.06.003

Ejemplares similares

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus
por: Craven, Claudia L., et al.
Publicado: (2017)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic
por: Paterson, Ross W., et al.
Publicado: (2018)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis
por: Banerjee, Gargi, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
por: Banerjee, Gargi, et al.
Publicado: (2020)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Amyloid-beta 42 adsorption following serial tube transfer
por: Toombs, Jamie, et al.
Publicado: (2014)

Complications of external cerebrospinal fluid drainage in aneurysmal subarachnoid haemorrhage
por: Arts, Sebastian, et al.
Publicado: (2021)

Compliance of the cerebrospinal space: comparison of three methods
por: Kazimierska, Agnieszka, et al.
Publicado: (2021)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4br11tajrvqtvoirsh4hfm8cev